• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic.

作者信息

Coombes Ian, Markwell Alexandra, Kubler Paul, Redmond Andrew M, McGurk Gordon, Roberts Jason A

机构信息

Royal Brisbane and Women's Hospital, Brisbane.

The University of Queensland, Brisbane.

出版信息

Aust Prescr. 2020 Jun;43(3):76-77. doi: 10.18773/austprescr.2020.030. Epub 2020 Apr 22.

DOI:10.18773/austprescr.2020.030
PMID:32675906
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7358057/
Abstract
摘要

相似文献

1
Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic.自我及他人的道德用药原则：新冠疫情期间的羟氯喹
Aust Prescr. 2020 Jun;43(3):76-77. doi: 10.18773/austprescr.2020.030. Epub 2020 Apr 22.
2
Medication of Hydroxychloroquine, Remdesivir and Convalescent Plasma during the COVID-19 Pandemic in Germany-An Ethical Analysis.德国 COVID-19 大流行期间羟氯喹、瑞德西韦和恢复期血浆的药物治疗-伦理分析。
Int J Environ Res Public Health. 2021 May 26;18(11):5685. doi: 10.3390/ijerph18115685.
3
Ethical issues related to the hydroxychloroquine treatment prescription for Covid-19.与新冠病毒疾病（Covid-19）羟氯喹治疗处方相关的伦理问题。
Ethics Med Public Health. 2020 Jul-Sep;14:100547. doi: 10.1016/j.jemep.2020.100547. Epub 2020 Jun 17.
4
Hydroxychloroquine Alternatives for Chronic Disease: Response to a Growing Shortage Amid the Global COVID-19 Pandemic.羟氯喹替代品在慢性病中的应用：全球 COVID-19 大流行背景下应对日益短缺的对策。
J Pharm Pract. 2022 Feb;35(1):120-125. doi: 10.1177/0897190020942658. Epub 2020 Jul 31.
5
The future is now: our experience starting a remote clinical trial during the beginning of the COVID-19 pandemic.未来已来：我们在 COVID-19 大流行初期启动远程临床试验的经验。
Trials. 2021 Sep 7;22(1):603. doi: 10.1186/s13063-021-05537-6.
6
Pandemic priorities: the impact of the COVID 19 pandemic on ethical leadership in the healthcare profession.大流行期间的优先事项：新冠疫情对医疗行业道德领导力的影响
Leadersh Health Serv (Bradf Engl). 2022 Jun 10;ahead-of-print(ahead-of-print). doi: 10.1108/LHS-02-2022-0011.
7
Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.羟氯喹与2019冠状病毒病：审视疾病公众形象对政策及临床决策的影响
J Med Ethics. 2020 Sep;46(9):574-578. doi: 10.1136/medethics-2020-106306. Epub 2020 Jul 9.
8
Identifying ethical values for guiding triage decisions during the COVID-19 pandemic: an Italian ethical committee perspective using Delphi methodology.确定 COVID-19 大流行期间指导分诊决策的伦理价值观：意大利伦理委员会使用德尔菲法的观点。
BMJ Open. 2021 May 18;11(5):e043239. doi: 10.1136/bmjopen-2020-043239.
9
Ethical review of off-label drugs during the COVID-19 pandemic.2019冠状病毒病大流行期间对超说明书用药的伦理审查
World J Clin Cases. 2022 Jun 16;10(17):5541-5550. doi: 10.12998/wjcc.v10.i17.5541.
10
Hydroxychloroquine prescribing habits and impact of the COVID-19 pandemic.羟氯喹的处方习惯及新冠疫情的影响
J Am Acad Dermatol. 2021 Feb;84(2):583-584. doi: 10.1016/j.jaad.2020.10.019. Epub 2020 Oct 16.

引用本文的文献

1
Path analysis of perceived disease vulnerability, COVID-19 fear, and lower vaccine hesitancy within the context of protection motivation theory.在保护动机理论背景下对感知到的疾病易感性、对新冠病毒的恐惧以及较低的疫苗犹豫程度进行路径分析。
Heliyon. 2024 Feb 11;10(4):e25889. doi: 10.1016/j.heliyon.2024.e25889. eCollection 2024 Feb 29.
2
Incidence of COVID-19 in patients under chronic treatment with hydroxychloroquine.接受羟氯喹长期治疗的患者中新冠病毒病的发病率。
Med Clin (Engl Ed). 2021 Feb 26;156(4):166-171. doi: 10.1016/j.medcle.2020.10.012. Epub 2021 Jan 23.
3
Immunosuppression for COVID-19: repurposing medicines in a pandemic.用于治疗新冠肺炎的免疫抑制：在大流行中重新利用药物。
Aust Prescr. 2020 Aug;43(4):106-107. doi: 10.18773/austprescr.2020.037. Epub 2020 Jun 17.
4
COVID-19 and the quality use of medicines: evidence, risks and fads.2019冠状病毒病与药品合理使用：证据、风险与时尚潮流
Aust Prescr. 2020 Jun;43(3):78-80. doi: 10.18773/austprescr.2020.031. Epub 2020 May 8.

本文引用的文献

1
A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.仓促下结论？有关羟氯喹治疗 COVID-19 的快速报告和结果传播及其后果。
Ann Intern Med. 2020 Jun 16;172(12):819-821. doi: 10.7326/M20-1223. Epub 2020 Mar 30.
2
Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.在大流行期间治疗新冠病毒病——超说明书用药、同情用药及随机临床试验
JAMA. 2020 May 19;323(19):1897-1898. doi: 10.1001/jama.2020.4742.
3
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus.2019 年更新版的 EULAR 系统性红斑狼疮治疗建议。
Ann Rheum Dis. 2019 Jun;78(6):736-745. doi: 10.1136/annrheumdis-2019-215089. Epub 2019 Mar 29.
4
The pitfalls of prescribing for family and friends.
Aust Prescr. 2016 Feb;39(1):11-3. doi: 10.18773/austprescr.2016.002. Epub 2015 Nov 6.
5
Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review.抗疟药物治疗系统性红斑狼疮的临床疗效和副作用：系统评价。
Ann Rheum Dis. 2010 Jan;69(1):20-8. doi: 10.1136/ard.2008.101766.
6
A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.一项关于系统性红斑狼疮中停用硫酸羟氯喹效果的随机研究。
N Engl J Med. 1991 Jan 17;324(3):150-4. doi: 10.1056/NEJM199101173240303.